China Insulin Industry Report, 2010
- Hard Copy
- Single User License
- Enterprise-wide License
(PDF Printable & Editable)
- Hard Copy + Single User License
In 2009, China’s insulin market size reached up to RMB5.3 billion, but still accounted for less than 6% of the global market. China has the world’s most diabetes patients, which is 92 million at present. In addition, the overall treatment rate of Chinese diabetes patients is less than 30%, and the per capita consumption of insulin is low, which is only about 0.8% of that of American patients. Therefore, China’s insulin market has great potential.
The insulin industry is a high-tech industry. China’s genetically engineered human insulin is still in the initial stage of industrialization, and has weak global competitiveness due to its high production cost and small production scale, which has led to the monopoly of imported insulin in China. In the first three quarters of 2010, Novo Nordisk, Eli Lilly and Sanofi-Aventis accounted for 90.6% of China’s insulin market, while Tonghua Dongbao, the largest domestic company, only accounted for 3.7%. In addition, more and more enterprises are entering the Chinese insulin market, such as The United Laboratories of Hong Kong and Bayer of Germany.
Enterprises in China’s Insulin Market by Market Share, Jan.-Sep.2010
Source: IMS, ResearchInChina
The report not only analyzes the status quo, competition pattern and development direction of the insulin industry as a whole and its market segments, but also makes a detailed analysis of the operation and development prospect of three foreign insulin producers including Novo Nordisk, Eli Lilly and Sanofi-Aventis as well as several large-scale domestic insulin producers.
Novo Nordisk of Denmark is an insulin industry leader in both China and the world; it accounted for 83.4% of China’s recombinant human insulin market and 52.2% of China’s insulin analog market in 2008.
Eli Lilly of the United States is the second pharmaceutical giant entering in China’s insulin market. It accounted for 12.3% of China’s recombinant human insulin market and 7.7% of China’s insulin analog market in 2008; it is expanding its presence in China. It invested over USD40 million in an insulin expansion project in Suzhou in 2009.
Sanofi-Aventis of France is the world's first producer of insulin glargine analog, and accounted for 36.1% of China’s insulin analog market in 2008.
Jilin Tonghua Dongbao is China's largest producer of recombinant human insulin; in 2010, its insulin API capacity was 3,000 kg and the insulin dosage form capacity was 70 million bottles in 2010.
Beijing Gan & Lee Pharmaceutical is a company controlled by Tonghua Dongbao. Gan & Lee and Sanofi Aventis are the world’s only two insulin glargine analog manufacturers.
Jiangsu Wanbang Biopharmaceuticals is a leading animal insulin enterprise in China, and occupied more than 80% of China’s animal insulin market in 2009. In addition, its animal insulin has been selected into the national catalog of essential drugs.
1. Overview of Insulin Industry
1.1 Definition & Classification
1.2 Industry Chain
2. International Environment for the Operation of China’s Insulin Market
2.1 Current Development
2.1.1 Market Size
2.1.2 R&D Direction of New Drugs
2.1.3 Production Process
2.2 Market Supply and Demand
2.3 Competition Pattern
2.4 Development Prospect
2.4.1 Increasingly Serious Diabetes Problem
2.4.2 Competitive Drugs or Alternative Therapies
2.4.3 Market Forecast
3. Status Quo & Prospect of China’s Insulin Market
3.1 Market Status
3.2 Market Supply & Demand
3.3 Competition Pattern
3.3.1 Foreign Monopoly
3.4 Industry Gross Margin and Price
3.5 Policy Environment
3.6 Development Prospect
3.6.1 Per Capita Consumption of Insulin will Increase
3.6.2 Market Share of Insulin will Increase
4. Import and Export of China's Insulin Market
4.1 Import & Export of Insulin and its Salts
4.2 Import & Export of Insulin-containing Drugs in Unfinished Dosage Form
4.3 Import& Export of Insulin-containing Drugs in Finished Dosage Form
5. Advantageous Enterprises in China’s Insulin Production Industry
5.1 Tonghua Dongbao
5.1.3 Marketing Strategy
5.1.4 Development Trend
5.1.5 Gan & Lee Pharmaceutical
5.2 Novo Nordisk
5.2.3 Operation in China
5.2.4 Development Trend
5.3 Eli Lilly
5.3.3 Operation in China
5.3.4 Development Trend
5.4.3 Operation in China
5.4.4 Development Trend
5.5 Wanbang Biopharmaceuticals
5.5.3 Development Prospect
Types of Diabetes
Classification and Characteristics of Insulin Dosage Forms (by Technology)
Classification and Typical Products of Insulin Dosage Forms (by Effective Time)
Insulin Industry Chain
Global Market Scale of Diabetes Drugs and Insulin Drugs, 2008-2010
Classification of Global Diabetes Drugs, 2010
R & D of Inhaled Insulin Dosage Form, 2006-2009
Global Insulin Pump Market Scale, 2009-2016
Recombinant Human Insulin Production Carrier and its Characteristics
Global Number of Diabetes Patients, 2005-2009
Global Theoretic Demand for Insulin API, 2009
Top Three Countries by Number of Diabetes Patients, 2009
Top Three Enterprises in Global Insulin Market, 2009
Sales of Major Producers in Global Insulin Analog Market, 2009
Drugs for the Immune Therapy of Type I Diabetes under Development, May 2010
Glucagon-like Peptide 1 (GLP-1)-related Drugs
Insulin Cell Transplantation Research Institutions and Progress, Dec. 2010
Global Market Scale of the Drugs for the Treatment of Type I Diabetes, 2007-2017
China’s Insulin Drug Market Scale, 2008-2009
Purchase Prices and YoY Growth of Some Insulin Products of Typical Hospitals in 22 Cities of China, 2009
Enterprises in China's Insulin Market by Market Share, Jan.-Sep. 2010
Enterprises in China’s Recombinant Human Insulin Market by Market Share, 2008
Enterprises in China's Insulin Analog Market by Market Share, 2008
Current or Potential Insulin Producers in China, 2010
Operating Gross Margin of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010
Prices of Common Insulin Products in China, 2009-2010
Insulin Included in the Health Insurance Directory of China, 2009
Average Insulin Utilization of Diabetes Patients by Country, 2009
Market Occupancy of China’s Insulin and Oral Hypoglycemic Drugs, 2007-2009
China’s Export Value and Prices of Insulin and its Salts, 2008-2010
China’s Export of Insulin and its Salts by Destination, Jan.-Nov. 2010
China’s Import Value and Prices of Insulin and its Salts, 2008-2010
China’s Import of Insulin and its Salts by Country of Origin, Jan.-Nov. 2010
China’s Cumulative Export Value of Insulin-containing Drugs in Unfinished Dosage Form, Jan.-Nov. 2010
China’s Export of Insulin-containing Drugs in Unfinished Dosage Form by Destination, Jan.-Nov. 2010
China’s Export Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010
China’s Export of Insulin-containing Drugs in Finished Dosage Form by Destination, Jan.-Nov. 2010
China’s Import Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010
China’s Import of Insulin-containing Drugs in Finished Dosage Form by Country of Origin, Jan.-Nov. 2010
Operating Income of Tonghua Dongbao, 2008-2010
Operating Income and Profit of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010
Sales Expenses and YoY Growth of Tonghua Dongbao, 2008-2010
Development of Tonghua Dongbao, 2009-2010
Hospital Procurement Amount of Beijing Gan & Lee Pharmaceutical, 2008-2009
Total Operating Income and Operating Profit of Novo Nordisk, 2008-2010
Main Businesses and Products of Novo Nordisk, H1 2010
Operating Income and YoY Growth of Recombinant Human Insulin and Insulin Analog of Novo Nordisk, 2008-2010
Novo Nordisk in China, 2009
Sales Revenue of Novo Nordisk by Region, 2007-2009
Development of Novo Nordisk, 2009-2011
Major Products of Eli Lilly, 2009
Total Operating Income and Profit of Eli Lilly, 2007-2010
Operating Income of Eli Lilly by Division, 2009
Operating Income of Humulin and Humalog of Eli Lilly, 2007-2010
Eli Lilly in China, 2010
Operating Income, Operating Expenses and Profit of Eli Lilly Suzhou Pharmaceutical, 2007-2008
Development of Eli Lilly, 2008-2013
Diabetes Products of Sanofi–Aventis, 2009
Operating Income and Profit of Sanofi-Aventis, 2007-2010
Operating Income of Insulin-related Products of Sanofi-Aventis, 2008-2010
Operating Income of Insulin-related Products of Sanofi-Aventis by Region, H1 2010
Sanofi-Aventis in China, 2010
Plants of Sanofi-Aventis in China, 2010,
Sanofi-Aventis’ Development in the Field of Insulin Products
Profile of Jiangsu Wanbang Pharmaceuticals
Insulin Products of Jiangsu Wanbang Pharmaceuticals, 2010
Net Income of Jiangsu Wanbang Pharmaceuticals by Main Business, 2007-2010
Unit Energy Consumption of Insulin Production of Jiangsu Wanbang Pharmaceuticals, 2008-2009
Development of Jiangsu Wanbang Pharmaceuticals, 2009-2010
Global and China Monoclonal Antibody Industry Report, 2013
In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...
China Insulin Industry Report, 2012-2015
China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...
China Heparin Industry Report, 2012-2014
China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...
China Blood Products Industry Report, 2011-2012
Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...
Company Study of Chongqing Zhifei Biological Products Co., Ltd, 2012
Chongqing Zhifei Biological Products Co., Ltd (Website：www.zhifeishengwu.com; Code：300122.SZ), hereinafter referred to as Zhifei Biological, was established in 1995 with the registered capital of RMB ...
Company Study of Walvax Biotechnology Co, Ltd.,2012
Walvax Biotechnology Co, Ltd. (Walvax Biotechnology for short), founded in 2001, specializes in research & development, production and marketing of bio-pharmaceutical vaccines. In September 2010, it w...
Company Study of Hualan Biological Engineering Ltd., 2011 (002007.SZ)
Hualan Biological Engineering Ltd., (hereinafter referred to as Hualan Biological) established in 1992, is a national key high-tech enterprise engaged in the R&D and production of blood products. ...
China Heparin Industry Report, 2010-2011
With richness in heparin materials and the quality of heparin API getting accredited by the international community, China has become one of the largest heparin API producers and exporters in the worl...
China Blood Products Industry Report, 2010-2011
Recent years have seen fast-growing development of blood product industry in China, with the enterprises concerned numbering 33 which can produce 10-odd blood products including human albumin, human i...
China Monoclonal Antibody Industry Report, 2010-2011
China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries in terms of industrialization. In 2010, the market...
China Insulin Industry Report, 2010
In 2009, China’s insulin market size reached up to RMB5.3 billion, but still accounted for less than 6% of the global market. China has the world’s most diabetes patients, which is 92 million at prese...
China Heparin Industry Report, 2010
Although it is with rich source of heparin raw materials, China lags behind in the manufacturing technologies for heparin drugs. Chinese heparin industry presents mainly the exportation of heparin API...
China Blood Products Industry Report, 2010
In 2009, Chinese blood products market valued nearly RMB7 billion and it will continue to expand in the next two or three years. The main reasons include:
The demand from the downstream of China bl...
Global and China Biopharmaceutical Industry Report, 2010
In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound annual growth rate of biopharmaceutical industry ...
China Blood Products Industry Report, 2009
The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict su...
China Listed Bio-pharmaceutical Companies Report, 2008
This report firstly gives an overview of China bio-pharmaceutical industry, and then analyses sub-industries, import & exports status of the industry; finally it expounds the operations and revenu...
China Blood Products Industry Report, 2007-2008
China blood products industry is all along comparatively independent from global blood products industry. In the year of 1986, according to the rules from Ministry of Health, China prohibited the impo...
China Biopharmaceutical Industry Report, 2007-2008
Pharmaceutical industry is a sunrise industry, especially the biopharmaceuticals, which just starts its large-scale industrialization process. Many large biotech and pharmaceutical companies are stren...